INMUNE BIO INC. Supplier Finance Program Obligation Decrease Settlement
INMUNE BIO INC. (INMB) reported Supplier Finance Program Obligation Decrease Settlement of $200.00 thousand for the 1-month period ending 2025-08-31, per its 10-Q filed 2025-10-30.
Financial Statements › Notes › Payables and Accruals
us-gaap:SupplierFinanceProgramObligationDecreaseSettlement · last filed 2025-10-30
- 2025-08-31: Supplier Finance Program Obligation Decrease Settlement 1 month $200.00K.
| Period end | Supplier Finance Program Obligation Decrease Settlement 1 month |
|---|---|
| 2025-08-31 | $200.00K 10-Q · filed 2025-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |